5 results
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
and CKD EMPA-REG ... outcomes in HFrEF on GDMT ... outcomes in HFrEF on GDMT ... visualabstract #table ... #CVD #CKD
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table ... -4 inhibitors SGLT2 ... Improved outcomes in CKD ... #comparison #management
Patient factors influencing the selection Of glucose-lowering drugs Other than SGLT2i and metformin in T2D and
metformin in T2D and CKD ... cardiovascular disease: CKD ... , #KDIGO2020 #CKD ... #Diabetes Management ... in CKD #management
Guideline-Directed Medical Therapy (GDMT) in HFrEF and CKD

 • Class I pillars of HFrEF GDMT across
Medical Therapy (GDMT ... ) in HFrEF and CKD ... pillars of HFrEF GDMT ... diuretics, MRA, SGLT2i ... #CKD #HFrEF #management
Stages in the development of HF and recommended therapy by stage. ACEI indicates angiotensin-converting enzyme inhibitor;
angiotensin-receptor blocker; CAD ... resynchronization therapy; DM, diabetes ... ejection fraction; GDMT ... ACCAHA #Algorithm #Management